english.prescrire.org > Spotlight > 100 most recent

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

In the April issue of Prescrire International: Towards better patient care - drugs to avoid in 2018

FREE DOWNLOAD Prescrire's annual review of drugs to avoid covers all the drugs examined by Prescrire between 2010 and 2017 that are authorised in the European Union or in France. We identified 90 drugs that are more harmful than beneficial in all the indications for which they have been authorised.
1 April 2018

Hepatitis C: sofosbuvir + velpatasvir (Epclusa°) represents an advance for some patients

The combination sofosbuvir + velpatasvir (Epclusa°) offers a therapeutic advance in the treatment of hepatitis C, especially in patients infected by a genotype 2 virus. But the uncertainty surrounding its adverse effects is unacceptable.
1 April 2018

New drugs and indications in 2017: numerous innovations offering no progress

Marketing authorisations often granted too hastily: patients are exposed to medicines with uncertain harm-benefit balances.
1 April 2018

Prescrire's ratings of new products and indications over the past 10 years

Each spring, Prescrire International publishes a recap of the drugs reviewed in our French edition during the previous year. It includes a table summing up the ratings Prescrire's editors gave to the new drugs and indications reviewed during each of the past ten years.
1 April 2018

Tripoliponumab: French firm Neuronodev demands withdrawal of marketing authorisation and approves 150 million euros for patients

1 April 2018

• Decline in vigilance: beware of collateral damage(s)

April Fool'sIn your dreams! Lulled by far too much information swirling around us day and night, it's no wonder we sometimes have trouble distinguishing between dreams and reality. So much so that one could almost believe a drug company would actually take the initiative to limit, and to pay for, the damage caused by one of its products. But that would be living in a dream world.
1 April 2018

Ceftazidime + avibactam (Zavicefta°). An option in the case of cephalosporin resistance

FEATURED REVIEW A ceftazidime + avibactam combination (Zavicefta°, Pfizer) has been approved in the European Union for the treatment of various “complicated” infections. In one clinical trial, the combination was as effective as a carbapenem and had an acceptable adverse effect profile.
Full review (2 pages) available for download by subscribers.
1 March 2018

In the March issue of Prescrire International: the annual Prescrire Awards for drugs, packaging and information

FREE DOWNLOAD The three annual Prescrire Awards are granted in total independence by the Prescrire Editorial Staff, based on reviews published over the past year in our French edition.
Full text available for free download.
1 March 2018

Hodgkin disease: two drugs that are not beneficial to patients

In the absence of any proven increase in life expectancy, there is no justification for exposing patients with Hodgkin disease to the many, sometimes severe, adverse effects of nivolumab (Opdivo°) and brentuximab vedotin (Adcetris°).
1 March 2018

Hospitalised children: errors detected by parents and family members

During a child's hospitalisation, family members often detect adverse events and errors which are not noticed or reported by caregivers.
1 March 2018

1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90